Dr. Wojciech Jurczak talks about Continues Therapy versus Time Limited Therapy in High-Risk CLL Patients
Dr. Wojciech Jurczak, Poland
Dr. Wojciech Jurczak, MD, PhD, from NIO-PIB im Marii Sklodowskeij-Curie in Krakow, Poland, discusses Continues Therapy versus Time Limited Therapy in High-Risk CLL Patients. During his session, he provided valuable information about targeted therapy being the standard of care for relapsed/refractory CLL patients, discussed on BCL-2 and BTK inhibitors and discussed the evolving landscape of CLL treatment approaches.
Explore more videos
Definition and Management of High-Risk CLL Patients
Dr. Ayman Al Hejazi, KSA
Panel Discussion
Dr. Ahmad Absi, KSA
Latest Updates in Management of CLL
Dr. Davide Rossi, Switzerland